2021
A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage
Martini RP, Siler D, Cetas J, Alkayed NJ, Allen E, Treggiari MM. A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care 2021, 36: 905-915. PMID: 34873674, DOI: 10.1007/s12028-021-01398-8.Peer-Reviewed Original ResearchConceptsSoluble epoxide hydrolaseAneurysmal subarachnoid hemorrhageSubarachnoid hemorrhageDHET ratiosEnd pointDay 7Day 10Primary study end pointSoluble epoxide hydrolase inhibitionCSF inflammatory cytokinesEET/DHET ratiosIncidence of DCIPrevention of DCITertiary end pointSecondary end pointsStudy end pointCerebral blood flowLength of stayEndothelial injury biomarkersEpoxide hydrolase inhibitionNeurovascular inflammationResultsTen patientsStudy drugAdverse eventsCytokine levels
2020
Randomized Pilot Trial of Acute Normovolemic Hemodilution in Pediatric Cardiac Surgery Patients
Harris WM, Treggiari MM, LeBlanc A, Giacomuzzi C, You JJ, Muralidaran A, Shen I. Randomized Pilot Trial of Acute Normovolemic Hemodilution in Pediatric Cardiac Surgery Patients. World Journal For Pediatric And Congenital Heart Surgery 2020, 11: 452-458. PMID: 32645767, DOI: 10.1177/2150135120923627.Peer-Reviewed Original ResearchConceptsPediatric cardiac surgery patientsAcute normovolemic hemodilutionCardiac surgery patientsSecondary end pointsSurgery patientsEnd pointPostoperative outcomesUsual careBlood transfusionCardiac surgeryNormovolemic hemodilutionHeart surgeryBlood productsPilot trialPediatric heart surgery patientsMarkers of morbidityAllogenic blood transfusionPrimary end pointHeart surgery patientsLong-term morbidityBlood conservation strategiesWorse postoperative outcomesPediatric heart surgeryIntensive care unitBlood component therapy
2019
Inhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients
Enomoto TM, Treggiari MM, Yanez ND, Merkel MJ. Inhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients. Respiratory Care 2019, 64: 743-751. PMID: 30967439, DOI: 10.4187/respcare.06426.Peer-Reviewed Original ResearchConceptsAcute right ventricular dysfunctionHeart transplant recipientsRight ventricular dysfunctionMechanical ventilationEnd pointHeart transplantationHospital stayTransplant recipientsVentricular dysfunctionHemodynamic valuesMedian numberAcute pulmonary hypertensionLength of ICUOrthotopic heart transplantationPrimary end pointSafety end pointSecondary end pointsImmediate postoperative periodPrimary vasodilatorVasoactive medicationsVasodilatory therapyPostoperative bleedingPulmonary hypertensionPostoperative periodConsecutive patients
2015
Dexmedetomidine Does Not Affect Evoked Potentials During Spine Surgery
Rozet I, Metzner J, Brown M, Treggiari MM, Slimp JC, Kinney G, Sharma D, Lee LA, Vavilala MS. Dexmedetomidine Does Not Affect Evoked Potentials During Spine Surgery. Anesthesia & Analgesia 2015, 121: 492-501. PMID: 26097987, DOI: 10.1213/ane.0000000000000840.Peer-Reviewed Original ResearchMeSH KeywordsAnesthesia, IntravenousAnesthetics, IntravenousDexmedetomidineDouble-Blind MethodEvoked PotentialsEvoked Potentials, MotorEvoked Potentials, SomatosensoryEvoked Potentials, VisualFemaleHumansHypnotics and SedativesIntraoperative Neurophysiological MonitoringMaleMiddle AgedOrthopedic ProceduresPiperidinesPropofolReaction TimeRemifentanilSpineTime FactorsConceptsEffect of dexmedetomidineVisual EPsSpine surgeryEnd pointElective spine surgeryPlacebo-controlled trialPrimary end pointSecondary end pointsLatency N1Motor EPsPlacebo groupStudy drugAdult patientsNormal salineLatency P1DexmedetomidineSomatosensory EPsIRB approvalRelevant dosesEP recordingInformed consentPatientsSurgeryEvoked PotentialsAnesthesia
2011
Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis
Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Investigators F. Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis. JAMA Pediatrics 2011, 165: 847-856. PMID: 21893650, PMCID: PMC3991697, DOI: 10.1001/archpediatrics.2011.136.Peer-Reviewed Original ResearchConceptsPseudomonas aeruginosa infectionCulture-based therapyCulture-based groupsCystic fibrosisAeruginosa infectionEarly Pseudomonas aeruginosa infectionTobramycin inhalation solutionPrimary end pointRate of exacerbationsExacerbation rateIntravenous antibioticsOral ciprofloxacinOral placeboAntibiotic regimensPulmonary exacerbationsAdverse eventsTreat analysisMulticenter trialAntipseudomonal treatmentInhalation solutionOdds ratioComparative efficacyPlaceboEnd pointFibrosis
2003
Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage.
Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. Journal Of Neurosurgery 2003, 98: 978-84. PMID: 12744357, DOI: 10.3171/jns.2003.98.5.0978.Peer-Reviewed Original ResearchConceptsDelayed ischemic neurological deficitsIschemic neurological deficitsHemodilution therapyNeurological deficitsSubarachnoid hemorrhageMethodological qualitySystematic reviewSummary relative risk estimatesRisk of deathMajor end pointsInternal validity scoreRelative risk estimatesStudy methodological qualityRandom-effects modelClinical vasospasmSymptomatic vasospasmCerebral vasospasmRegister searchMAIN OUTCOMEValidity scoresReference listsPaucity of informationVasospasmEnd pointRisk estimates
2002
Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age?
Weiss NS, Treggiari MM. Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age? Obstetrics And Gynecology 2002, 100: 364-8. PMID: 12151165, DOI: 10.1016/s0029-7844(02)02046-x.Peer-Reviewed Original ResearchConceptsLong-term hormone useOlder postmenopausal womenPostmenopausal womenHormone useFracture riskYounger postmenopausal womenPostmenopausal hormone useSurrogate end pointsBone mineral densityUse of hormonesHormone therapySkeletal benefitsRandomized trialsSuch therapyMineral densitySkeletal fracturesAbsolute reductionEnd pointStudy of hormonesWomenHealth careTrialsAgeTrue declineRisk